Surgery and mesothelioma: If not randomization, at least standardization and registration!

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 1-2

  Pass, Harvey ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SEVERITY; EDITORIAL; HUMAN; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA MESOTHELIOMA; MEDIASTINOSCOPY; MORBIDITY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; STANDARDIZATION;

HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; THORACOTOMY;

EID: 78650212127     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.007     Document Type: Editorial

References (10)

1. Richards W.G., Godleski J.J., Yeap B.Y., Corson J.M., Chirieac L.R., Zellos L., et al. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 2010, 116:1510-1517.
2. Wolf A.S., Daniel J., Sugarbaker D.J. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg 2009, 21:132-148.
3. Flores R.M., Pass H.I., Seshan V.E., Dycoco J., Zakowski M., Carbone M., et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135:620-626.
4. Pass H.I., Temeck B.K., Kranda K., Steinberg S.M., Feuerstein I.R. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998, 115:310-317.
5. Bolukbas S., Manegold C., Eberlein M., Bergmann T., Fisseler-Eckhoff A., Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/permetrexed and radiotherapy. Lung Cancer 2009.
6. Neragi-Miandoab S., Richards W.G., Sugarbaker D.J. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg 2008, 6:293-297.
7. Luckraz H., Rahman M., Patel N., Szafranek A., Gibbs A.R., Butchart E.G. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg 2010, 37:552-556.
8. Pass H.I., Goparaju C., Ivanov S., Donington J., Carbone M., Hoshen M., et al. hsa-miR-29c is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010, 70:1916-1924.
9. Gordon G.J., Dong L., Yeap B.Y., Richards W.G., Glickman J.N., Edenfield H., et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 2009, 101:678-686.
10. Nowak A.K., Francis R.J., Phillips M.J., Millward M.J., van der Schaaf A.A., Boucek J., et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010, 16:2409-2417.